Given the prevalence of AR mutations in advanced CRPC, defining their activity in more robust and disease-relevant models is imperative to help improve our understanding of these receptors and to potentially exploit their distinct activities for the development of new PC treatments. This evidence concerns the gene AR and pachyonychia congenita.